See more : LCI Industries (LCII) Income Statement Analysis – Financial Results
Complete financial analysis of Carmell Therapeutics Corporation (CTCX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Carmell Therapeutics Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Natura &Co Holding S.A. (NTCO) Income Statement Analysis – Financial Results
- F-Tech Inc. (7212.T) Income Statement Analysis – Financial Results
- ACM Research (Shanghai), Inc. (688082.SS) Income Statement Analysis – Financial Results
- IVF Hartmann Holding AG (VBSN.SW) Income Statement Analysis – Financial Results
- Alpine Acquisition Corporation (REVE) Income Statement Analysis – Financial Results
Carmell Therapeutics Corporation (CTCX)
About Carmell Therapeutics Corporation
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 124.79K | 242.56K | 0.00 |
| Gross Profit | -124.79K | -242.56K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.50M | 2.20M | 982.84K |
| General & Administrative | 0.00 | 3.22M | 863.33K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.60M | 3.22M | 863.33K |
| Other Expenses | 0.00 | 10.92K | 37.38K |
| Operating Expenses | 5.09M | 5.51M | 1.94M |
| Cost & Expenses | 5.22M | 5.51M | 1.94M |
| Interest Income | 0.00 | 2.25M | 8.09K |
| Interest Expense | 889.32K | 3.75M | 2.50M |
| Depreciation & Amortization | 124.79K | 242.56K | 242.12K |
| EBITDA | -15.19M | -5.25M | -1.66M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.22M | -5.51M | -1.94M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.99M | -3.54M | -4.54M |
| Income Before Tax | -16.21M | -9.05M | -6.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -760.16K | 391.20K | 2.54M |
| Net Income | -15.45M | -9.05M | -6.48M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -1.46 | -0.46 | -0.33 |
| EPS Diluted | -1.46 | -0.46 | -0.33 |
| Weighted Avg Shares Out | 11.02M | 19.77M | 19.77M |
| Weighted Avg Shares Out (Dil) | 11.02M | 19.77M | 19.77M |
Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index
Carmell Corp (Nasdaq: CTCX) announced the appointment of Kendra Bracken-Ferguson as CEO effective July 30, 2024 with Rajiv Shukla continuing as Chairman.
Carmell Announces Successful Closing of $3.0 Million Private Placement
PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of its previously announced private placement with new and...
Carmell Announces $3.0 Million Private Placement
PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a securities purchase agreement with new and...
Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction
PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the successful closing of the previously announced sale of its wholly...
Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary
PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the execution of a definitive agreement to sell its wholly owned...
Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field
PITTSBURGH, March 18, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced it will host an Investor Webinar titled “Unveiling the Secretome: On the Eve of...
Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024
PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced that they have completed product development of their Gold Limited Edition Exclusive (G.L.E.E.) product...
Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors
PITTSBURGH, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a human biomaterials company (“Carmell”), today announced the addition of two independent directors to their Board.
Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine
FLAGSTAFF, Ariz. , Sept. 12, 2023 /PRNewswire/ -- Moonshot is excited to announce that its incubator client, Axolotl Biologix, based in its NACET Flagstaff, Arizona campus, has finalized a merger with Carmell Therapeutics (Nasdaq: CTCX).
Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics
PITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX) (“Carmell”), a regenerative care company, today announced the completion of post-merger integration with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company (“Axolotl”).
Source: https://incomestatements.info
Category: Stock Reports